IL-FRISS
13.4.2021 17:05:12 CEST | Business Wire | Press release
FRISS , the market leader in AI-powered fraud, risk and compliance solutions for P&C insurance carriers, today announced the acquisition of Terrene Labs . Industry leaders in providing Commercial Insurance providers with comprehensive Risk Insights, Terrene will be a fundamental addition to the FRISS product family. Commercial lines underwriters now have access to thousands of actionable insights within just 5 seconds, replacing a disjointed manual and limited enrichment process that previously took up to a week and delayed policies for quality customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005837/en/
“We’re bringing commercial lines to the digital age together,” remarked FRISS CEO and Co-founder Jeroen Morrenhof . “True risk insights were always hard to access and we’re changing that. Combined with the analytics capabilities of FRISS, vast data will no longer be so overwhelming – our customers can now make better decisions and they can make them much faster.”
Both the FRISS and Terrene teams distinguish themselves in the marketplace with deep domain knowledge, with over 1,000 years of combined insurance experience. Customers will be able to take advantage of the full end-to-end product suite to screen submissions, policies, endorsement, renewals, book rollovers and claims, utilizing a trove of data sources, images, and social networks, all in real-time through a holistic approach applying predictive analytics and AI.
The acquisition follows FRISS’s announcement of a record year, in which they showed a 58% revenue growth and doubled their client base in North America. By acquiring Terrene, FRISS onboards a market proven product, strong customer base and deep industry knowledge that will strengthen their position as a true industry partner. Terrene products will join the FRISS product suite as Underwriting Insights and will help commercial lines insurers immediately identify every angle of risk. Underwriting Insights will be available immediately as a standalone product, and will soon integrate with the end-to-end solutions already offered by FRISS.
With a singular focus on the insurance industry, FRISS and Terrene tackle all aspects of fraud detection and risk insights respectively. Their offerings are highly synergistic and work seamlessly to solve the issues carriers face in their quest toward end-to-end digital underwriting. Combined, the companies deliver instant protection against unwanted risks, helping revitalize insurance so that carriers can focus on an efficient customer experience without the looming threat of dishonesty.
“Carriers have to be smarter and quicker in the way they assess risk in today’s dynamic environment, and that’s what our team helps them do,” shared Terrene Labs CEO and Founder Piyush Singh . “We’re excited to join the forward-thinking vision of the FRISS team to accelerate the mission to solve our customers’ most pressing issues together.”
To learn more about FRISS Underwriting insights and watch a quick demo here .
About Terrene Labs
Led by a team of industry experts, Terrene provides solutions for next-generation digital underwriting. Turning a manual, multi-day process into an automated solution that arrives in seconds, Terrene takes the chore out of an underwriter’s job and allows them to focus on the tasks that really matter. Terrene customers appreciate the long-term value of instantly understanding every risk in their book of business, proven through the loyalty and strong relationship of their customer base.
About FRISS
With over 200 implementations, FRISS is recognized globally as the leading provider of AI-powered fraud detection and prevention software for the P&C industry. As the longest operating dedicated provider, FRISS has diligently evolved to meet the changing needs of their customers, especially as the industry enters the accelerated change of the digital age of insurance. No other company offers the depth of experience and holistic focus on fraud detection and prevention found at FRISS. FRISS customers appreciate their unique focus on insurance fraud prevention and the dedication they show to their customers’ success. Learn more at www.friss.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005837/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom